How Biologics Are Changing the Global Burden of Inflammatory Bowel Disease: A Review

Inflammatory bowel disease (IBD), comprising Crohn's disease and ulcerative colitis, has evolved from a condition concentrated in high-income Western nations into a global disease. The therapeutic landscape has been transformed by biologic agents, including anti-tumor necrosis factor (anti-TNF) antibodies, anti-integrin therapy (vedolizumab), interleukin (IL)-12/23 blockade (ustekinumab), and selective IL-23 (p19) inhibitors (risankizumab and mirikizumab); more recently, oral small-molecule advanced therapies (Janus kinase (JAK) inhibitors and sphingosine-1-phosphate (S1P) receptor modulators) have broadened the treatment armamentarium further. This narrative review synthesizes contemporary epidemiological data such as incidence, prevalence, mortality, disability, healthcare utilization, and economic burden, and landmark randomized controlled trials (RCTs) to examine how biologic therapy is reshaping the global burden of IBD. We summarize the mechanisms and pivotal efficacy evidence for each major class, and we appraise their measurable impact on hard outcomes, mucosal healing, surgery, hospitalization, disability, and quality of life, alongside the comparative-effectiveness data emerging from head-to-head trials. We then consider an apparent paradox: although biologics reduce complications in trial settings, population-level reductions in surgery and hospitalization have been inconsistent, and the cost of IBD care has shifted toward pharmaceuticals and risen overall. Finally, we address the role of biosimilars in improving affordability and the persistent access divide between high-income and resource-limited settings. Because much of the population-level evidence is ecological or observational, associations between biologic use and improvements in mortality and disability should be interpreted with caution and cannot be regarded as proof of direct causation. Biologics have unquestionably improved the lives of individual patients; whether they reduce the global burden of IBD will depend on equitable access, optimal positioning, and integration with treat-to-target strategies.